Bladder & Urothelial Cancer Excellence Forum

Bladder & Urothelial Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Pembrolizumab-Based Bladder Preservation Strategy in Muscle-Invasive Bladder Cancer

04/01/2026

Jonathan Anker, MD, PhD

Jonathan Anker, MD, PhD, discusses results from the phase 2 HCRN GU 2444 study evaluating a response-adapted bladder preservation strategy among cisplatin-ineligible patients with muscle-invasive bladder cancer.

Jonathan Anker, MD, PhD,...

04/01/2026

Oncology

Matthew Galsky, MD, Icahn School of Medicine at Mount Sinai

Videos

FX-909 Shows Biomarker-Driven Activity in Advanced Urothelial Cancer

03/02/2026

Matthew Galsky, MD

Matthew Galsky, MD, discusses results from a phase 1 study evaluating FX-909 in patients with advanced urothelial cancer.

Matthew Galsky, MD, discusses...

03/02/2026

Oncology

Videos

Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Muscle-Invasive Bladder Cancer

03/02/2026

Matthew Galsky, MD

Matthew Galsky, MD, discusses results from the phase 3 KEYNOTE-B15/EV-304 study evaluating perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer.

Matthew Galsky, MD, discusses...

03/02/2026

Oncology

Videos

RETAIN-2 Supports Response-Adapted Bladder Preservation in Muscle-invasive Bladder Cancer

02/27/2026

Pooja Ghatalia, MD

Pooja Ghatalia, MD, discusses results from the phase 2 RETAIN-2 trial and integrated ctDNA analysis from RETAIN-1 and RETAIN-2 evaluating response-adapted bladder preservation in muscle-invasive bladder cancer.

Pooja Ghatalia, MD, discusses...

02/27/2026

Oncology

Thomas Powles, MD, MBBS, Barts Cancer Institute

Videos

Enfortumab Vedotin and Pembrolizumab Among Patients With Advanced Urothelial Cancer in the First-Line Setting

04/11/2024

Featuring Thomas Powles, MBBS, MD

Featuring Thomas Powles, MBBS, MD ...

Thomas Powles, MBBS, MD, discusses results from the phase 3 EV-302 trial, which found enfortumab vedotin plus pembrolizumab improved survival outcomes among patients with previously untreated advanced urothelial carcinoma.

Thomas Powles, MBBS, MD,...

04/11/2024

Oncology

Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center

Podcasts

Sacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 Trial

03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...

Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.

Petros Grivas, MD, PhD, shares...

03/07/2024

Oncology

Andrea Apolo, MD, National Cancer Institute

Conference Coverage

Adjuvant Pembrolizumab New Therapeutic Option For High-Risk Muscle-Invasive Bladder Cancer

02/05/2024

Andrea Apolo, MD

At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.

At the 2024 ASCO GU Cancers...

02/05/2024

Oncology

Conference Coverage

HER2 and PD-L1 Immunohistochemistry Expression Among Patients With Advanced Bladder Cancer

01/30/2024

David Aggen, MD, PhD

David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...

David Aggen, MD, shares insights...

01/30/2024

Oncology

Conference Coverage

Enfortumab Vedotin Plus Pembrolizumab Potential New Standard of Care for Advanced Urothelial Carcinoma in the First-Line Setting

01/26/2024

Michiel van der Heijden, MD

Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.

Michiel van der Heijden, MD,...

01/26/2024

Oncology

Arlene Siefker-Radtke, MD, MD Anderson Cancer Center

Videos

Erdafitinib Shows Similar OS to Pembrolizumab Among Patients With FGFR-Altered Advanced/Metastatic Urothelial Carcinoma

11/16/2023

Arlene Seifker-Radtke, MD

Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.

Arlene Siefker-Radtke, MD,...

11/16/2023

Oncology

Recent News

News

Pembrolizumab Yields Meaningful Benefit in Advanced Urothelial Cancer

07/27/2020

Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.

Pembrolizumab was active in...

07/27/2020

Oncology

News

Switch Maintenance Pembrolizumab Improves Response, PFS in Metastatic Urothelial Cancer

05/01/2020

Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.

Switch maintenance pembrolizumab...

05/01/2020

Oncology

News

Enfortumab Vedotin Monotherapy Yields Durable Responses in Metastatic Urothelial Cancer

02/26/2020

Enfortumab vedotin monotherapy has demonstrated meaningful and durable responses in patients with metastatic urothelial cancer.

Enfortumab vedotin monotherapy...

02/26/2020

Oncology

FDA Approval

FDA Approves Pivekimab Sunirine for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasms

05/27/2026

Emily Estrada

Based on results from the phase 2 CADENZA trial, the FDA has approved pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms.

Based on results from the phase...

05/27/2026

Oncology

News

Lorlatinib Maintains Long-Term Benefit in Advanced ALK-Positive Non-Small Cell Lung Cancer

05/27/2026

Emily Estrada

Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.

Updated results from the phase 3...

05/27/2026

Oncology

News

Neoadjuvant Lorlatinib Produces Durable Early Outcomes in ALK-Positive NSCLC

05/27/2026

Emily Estrada

Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.

Results from a multicenter phase...

05/27/2026

Oncology

News

Trastuzumab Rezetecan Shows Strong Clinical Promise in HER2-Positive Advanced Colorectal Cancer

05/27/2026

Emily Estrada

According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.

According to results from a...

05/27/2026

Oncology

News

Delayed Interval Surgery After Extended Neoadjuvant Chemotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer

05/26/2026

Stephanie Holland

Results from the 2 CHRONO trial demonstrated that delaying interval surgery until after 6 cycles of neoadjuvant chemotherapy did not significantly improve survival in advanced ovarian cancer.

Results from the 2 CHRONO trial...

05/26/2026

Oncology

News

Relacorilant Plus Nab-Paclitaxel Improves Overall Survival in Platinum-Resistant Ovarian Cancer

05/26/2026

Stephanie Holland

Final subgroup analyses from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel significantly improved overall survival in platinum-resistant ovarian cancer.

Final subgroup analyses from the...

05/26/2026

Oncology

News

Carboplatin Plus Mirvetuximab Soravtansine Fails to Improve PFS in FRα-High Platinum-Eligible Recurrent Ovarian Cancer

05/26/2026

Stephanie Holland

Results from the phase 2 MIROVA/AGO-OVAR 2.34 trial demonstrated that carboplatin plus mirvetuximab soravtansine did not improve progression-free survival in patients with platinum-eligible relapsed ovarian cancer with high FRα expression.

Results from the phase 2...

05/26/2026

Oncology

News

Dostarlimab Plus Chemotherapy Demonstrates Sustained Disease Control in dMMR/MSI-H Advanced Endometrial Cancer

05/26/2026

Stephanie Holland

Updated results from the phase 3 RUBY trial showed durable PFS benefit with dostarlimab plus chemotherapy in dMMR/MSI-H advanced or recurrent endometrial cancer, with modeling analyses suggesting potential long-term cure in a substantial...

Updated results from the phase 3...

05/26/2026

Oncology

News

Detalimogene Voraplasmid Shows Promise in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

05/22/2026

Emily Estrada

Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.

Interim results from cohort 1 of...

05/22/2026

Oncology

News

Extended Pelvic Lymph Node Dissection Shows Selective Benefit in Patients With Prostate Cancer

05/22/2026

Emily Estrada

Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...

Long-term results from a phase 3...

05/22/2026

Oncology